ABclonal Technology, a US-based provider of customised biology research reagents and services, announced on Friday that it has closed 600 million yuan ($91.8 million) in a Series C round of financing led by healthcare-focused investor LYFE Capital.
Sequoia Capital China, Xiamen C&D Emerging Industry Equity Investment — the equity investment arm of Chinese modern service firm Xiamen C&D Inc — and Suzhou-based fund of funds (FOF) manager Oriza FoFs participated in the deal.
